That is aside from reduced dose aspirin and low molecular excess weight heparin. have had an experimental drug as part of another clinical trial in thirty times of starting the trial cure It blocks a gene  referred to as JAK2. By blocking JAK2 ruxolitinib slows down or stops the most https://zanubrutinib22109.answerblogs.com/26267057/a-review-of-navitoclax